CSL Behring
Biotherapies for Life™

CSL Research Acceleration Initiative

Applications close 12th March 2021

WHY COLLABORATE WITH CSL?

Global Capabilities on your doorstep

Work with one of the world's leading biotech companies

Funding for successful proposals

Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise

Accelerate translation of your research to deliver new therapies to patients

CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations.

The 2021 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.



Successful applicants will receive up to USD 200k p.a. for up to 2 years (max USD 400k funding).

Researchers who wish to apply are required to submit a 300 word online pre-application by **12th March 2021** via the following link https://servicesplatform.partneringplace.com/OppPortal/portal/csl/.
Shortlisted applicants will then be invited to submit a detailed proposal in April.

Interested researchers are invited to join an online information session to learn more. Times and links will be announced separately by your Research or Innovation Office.
Please note: only Researchers from registered Institutions are eligible to apply

CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications in the following **Focus Areas**:

Therapeutic Areas	 Immunology	 Hematology	 Respiratory	 Cardiovascular and Metabolic	 Transplant
Modalities	**Antibodies**	**Recombinant Proteins**	**Cell and Gene Therapies**	Small molecules **NOT** of interest	

Focus Areas

Autoimmune diseases
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms of:
Sjögren's syndrome, Systemic sclerosis, SLE, Pemphigus vulgaris, Hidradenitis suppurativa, Dermatomyositis, other rare rheumatological/ dermatological conditions

Inflammation
Novel strategies to modulate the immune system to treat inflammatory diseases (including neuroinflammation e.g. CIDP)

Next generation IVIG / alternatives to plasma-derived IVIG

Sickle cell disease
Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy

Ischemic and hemorrhagic stroke
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms

Focus on neuro- and thrombo-inflammation/ novel thrombolytics

Biomarker/Omics approaches for patient stratification and drug discovery

Hemophilia
In vivo gene-editing and technologies for liver targeted delivery

Interstitial lung diseases
(progressive, fibrosing)
Novel biologic targets/ therapeutics

Biomarker/Omics approaches for patient stratification and drug discovery

Novel animal and human disease models

Acute respiratory distress syndrome
Novel biologic targets/ therapeutics

Biomarker/Omics approaches for patient stratification and drug discovery

Alpha-1 antitrypsin deficiency
In vivo gene-editing and technologies for liver targeted delivery

Rare lipid disorders
(e.g. Familial hypercholesterol-emia, Familial chylomicronemia)
In vivo gene-editing and technologies for liver targeted delivery

Severe forms of atherosclerosis
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms

Refractory angina
Novel biologic targets/ therapeutics

Myocarditis
Novel biologic targets/ therapeutics

Novel animal and human disease models

Access to patient samples

Tolerance
(Solid organ transplant/HSCT)
Novel strategies or biologics to induce tolerance (T regs, T cell anergy and/or tolerogenic DCs)

Graft vs host disease
Novel biologic targets/ therapeutics to modulate the immune response for treatment and prevention

Acute rejection
(Antibody-mediated rejection)
Novel biologic targets/ therapeutics to modulate the immune response

Hematopoietic stem cell transplants
Strategies to improve efficacy/ safety, including inducing stem cell mobilisation, reducing toxicity of BM conditioning, improvement of engraftment

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.